Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical JAK inhibition (Anzupgo) for cutaneous T-cell lymphoma (mycosis fungoides)
2025-523472-23-01Phase 2Authorised
- Sponsor
- Central Denmark Region
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of delgocitinib in cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF), sponsored by Central Denmark Region. Primary endpoints: Skin response by mSWAT change at Week 16, Overall skin response category and 1 more. Planned start Aug 2026; status: authorised.
02
Drugs
delgocitinib
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on 2025-523472-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523472-23-01.